Background {#Sec1}
==========

Neurotransmission underlies cognition and behavior, and when disturbed leads to changes in these functional parameters \[[@CR1]\]. The polyunsaturated fatty acids (PUFAs), docosahexaenoic acid (22:6n-3, DHA) and arachidonic acid (20:4n-6, AA) are important second messengers in brain, where they participate in neurotransmission \[[@CR2]\]. Agonist binding to certain neuroreceptors can release AA or DHA from the stereospecifically numbered-2 (*sn*-2) position of membrane phospholipids via activation of AA-selective group IVA calcium-dependent cytosolic phospholipase A~2~ (cPLA~2~) or DHA-selective group VIA calcium-independent phospholipase A~2~ (iPLA~2~) \[[@CR3]\]. cPLA~2~ and iPLA~2~ are post-synaptically located \[[@CR4], [@CR5]\].

In the intact brain and *in vitro*, AA-preferring cPLA~2~ type IVA has been shown to be coupled to serotonergic 5-HT~2A/2C~ receptors \[[@CR6], [@CR7]\], cholinergic muscarinic M~1,3,5~ receptors \[[@CR8]--[@CR10]\], dopaminergic (D)2-like receptors \[[@CR11]--[@CR14]\], and ionotropic N-methyl-D-aspartate (NMDA) receptors \[[@CR15], [@CR16]\]. iPLA~2~, which is DHA-preferring, can be activated by agonist stimulation of cholinergic muscarinic M~1,3,5~ and serotonergic 5-HT~2A/2C~ receptors, but not of NMDA receptors \[[@CR9], [@CR16], [@CR17]\].

The regulation of G-protein mediated activation of cPLA~2~ or iPLA~2~ depends on extracellular and intracellular calcium concentrations. cPLA~2~ is activated by extracellular Ca^2+^ entry into the cell and iPLA~2~ by intracellular calcium release from the endoplasmic reticulum via phospholipase C (PLC) (reviewed in \[[@CR18]\]). PLC, when activated, converts membrane phosphatidylinositol 4,5-bisphosphate (PIP~2~) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP~3~). IP~3~ binding to IP~3~ receptors stimulates the release of intracellular Ca^2+^ \[[@CR19], [@CR20]\] and of calcium influx factor \[[@CR21]\] from the endoplasmic/sarcoplasmic reticulum (ER/SR). The calcium influx factor contributes to the activation of iPLA~2~ by dissociating calmodulin from the active site of iPLA~2~ \[[@CR22], [@CR23]\]. This PLC-mediated activation of iPLA~2~ results in the hydrolysis of DHA from membrane phospholipid. DAG can also be further hydrolyzed to release DHA, although this pathway likely contributes minimally to DHA release.

Intracellular calcium release associated with activation of the PLC pathway regulates vesicle transport and neurotransmitter release at synaptic terminals \[[@CR19], [@CR24]\]. Muscarinic M~1,3,5~ and serotonergic 5-HT~2A/2C~ neurotransmission is coupled to iPLA~2~ via the PLC pathway, as is dopaminergic neurotransmission, although the directionality of this coupling is not agreed on. Activation of D2-like receptors in isolated neurons or dissected brain structures was reported to increase \[[@CR19], [@CR20], [@CR25], [@CR26]\] or decrease \[[@CR27], [@CR28]\] intracellular calcium release or IP~3~ concentration \[[@CR29]\]. A reduction in intracellular calcium release would not activate iPLA~2~, whereas an increase would activate iPLA~2~ and increase DHA release.

In the present study, we wished to see if activation of brain D2-like receptors in unanesthetized rats would also lead to a DHA signal, as it does an AA signal \[[@CR11], [@CR12]\]. Stimulation of dopaminergic receptors by the agonists quinpirole or apomorphine produced an AA signal that could be blocked by the D2 receptor antagonists raclopride or butaclamol in unanesthetized rats \[[@CR11], [@CR12], [@CR14]\].

To test this, we used an established *in vivo* kinetic method in awake rats \[[@CR16]\], to quantify the DHA signal in response to the D2-like receptor agonist quinpirole, compared with vehicle. With this method, radiolabeled DHA is infused to steady state levels in plasma, and brain radioactivity is measured with quantitative autoradiography to derive the regional incorporation coefficient, k\*. We found that D2-like receptor activation with quinpirole did not change the DHA incorporation coefficient (k\*) into brain compared to vehicle-treated controls, suggesting that D2-like receptor activation does not involve DHA release as a second messenger.

Methods {#Sec2}
=======

Animals and diets {#Sec3}
-----------------

Experiments were conducted following the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health Publication No. 86--23) and were approved by the Animal Care and Use Committee of *Eunice Kennedy Shriver* National Institute of Child Health and Human Development. Two-month-old male Fischer CDF 344 rats (Charles River Laboratories, Wilmington, MA) were acclimated for one month in an animal facility with regulated temperature, humidity and 12-h dark/light cycle. Rats were maintained on the Rodent NIH-31 auto 18--4 diet (Zeigler Bros, Gardens, PA), which contained (as% of total fatty acid) 20.1% saturated, 22.5% monounsaturated, 47.9% linoleic, 5.1% α-linolenic, 0.02% arachidonic, 2.0% eicosapentaenoic, and 2.3% docosahexaenoic acid \[[@CR30]\]. Water and food were provided ad libitum.

Tracer purification and drug preparation {#Sec4}
----------------------------------------

Radiolabeled \[1-^14^C\]DHA dissolved in ethanol (53 mCi/mmol, Moravek Biochemicals, Brea, CA) was purified on 60 A° thin-layer chromatography (TLC) silica plates (\~5 mg per 3 cm lane on each plate) alongside phospholipid, cholesterol, cholesteryl ester, triglyceride and unesterified fatty acid standards using diethyl ether: heptane: acetic acid (60:40:3 v/v) as a solvent. The \[1-^14^C\]DHA was purified because the stock tracer bottles used for this study had been opened in the past, a factor which was previously found to reduce tracer purity over time despite storing it in a −80°C freezer, due to loss of the preservative argon gas blanket in the stock bottle once opened. The plate was sprayed with 0.03% 6-p-toluidine-2-naphthalene-sulfonic acid in 50 mM Tris--HCl buffer (pH7.4) (w/v), and the unesterified fatty acid band containing \[1-^14^C\]DHA was identified under UV light, scraped and purified from the silica particles by the Folch method (in 30 ml 2:1 v/v chloroform/methanol and 7.5 ml 0.5 M KCl). The chloroform extract was dried under nitrogen, reconstituted twice with 10 ml ethanol, centrifuged to remove additional silica particles, and pipetted to a new 50 ml Pyrex tube. The ethanol extract was reconstituted in 5 ml of ethanol. Radioactive purity measured in a portion of the ethanol extract with HPLC using acetonitrile/water (90/10%) as a solvent (constant flow rate of 2 ml/min), confirmed that 93% of the radioactivity eluted at the same time as the unesterified DHA (unlabeled) standard. On the day of the experiment, a portion of the ethanol extract was dried under nitrogen and resuspended in HEPES buffer, pH 7.4, containing 50 mg/ml fatty acid-free bovine serum albumin (Sigma-Aldrich, St Louis, MO).

An acute 1 mg/kg i.v. dose of (−)-quinpirole hydrochloride dissolved in 0.9% saline (Sigma-Aldrich) was chosen because it produces widespread significant increments in the incorporation coefficient, k\*, for AA in the brain of unanesthetized rats, which can be blocked by the D2-like receptor antagonists, butaclamol or raclopride, without causing convulsions \[[@CR12], [@CR14], [@CR31]\].

Surgical procedures and tracer infusion {#Sec5}
---------------------------------------

A total of 16 rats were randomized to saline or quinpirole treatment (n = 8 per treatment). Rats were anesthetized with halothane (2--3% v/v in O~2~) and polyethylene (PE 50) catheters were surgically inserted into the right femoral artery and vein (4 rats per day, 2 saline and 2 quinpirole) \[[@CR31]\]. The wound was closed with surgical clips and the rat was wrapped loosely, with its upper body remaining free, in a fast-setting plaster cast taped to a wooden block. Each surgery lasted 20--25 min. Rats were allowed to recover from anesthesia for 3--4 h in an environment maintained at 25°C. Rectal temperature was maintained at 36.5-37.5°C using a feedback-heating device and rectal thermometer. Arterial blood pressure and heart rate were measured with a blood pressure recorder (CyQ 103/302; Cybersense, Nicholasville, KY). One minute after an i.v. injection of quinpirole or saline, \[1-^14^C\]DHA (170 μCi/kg, 2 ml) was infused into the femoral vein for 5 min at a rate of 400 μl/min, using an infusion pump (Harvard Apparatus Model 22, Natick, MA). Blood was collected at baseline and after \[1-^14^C\]DHA infusion (time of collection: 0, 0.2, 0.35, 0.75, 1.5, 3.0, 4.0, 4.9, 5.5, 6.5, 7.5, 10.0, and 19.0 min). Twenty min after beginning tracer infusion, the rat was euthanized with an overdose of Nembutal® (90 mg/kg, i.v.) and decapitated. The brain was removed, frozen in 2-methylbutane maintained at −40°C in dry ice, and stored at −80°C until sectioned.

Chemical analysis {#Sec6}
-----------------

Blood samples, collected before, during or after \[1-^14^C\]DHA infusion, were centrifuged immediately at 18,000 *g* for 30 s at room temperature. Total lipids were extracted from plasma (30 μl) using a modified Folch procedure \[[@CR32]\]. One hundred μl of the lower organic phase was used to determine the radiolabeled unesterified plasma \[1-^14^C\]DHA concentration by liquid scintillation counting.

Concentrations of unlabeled, unesterified fatty acids were determined from 100 μl of ice-thawed arterial plasma collected at 20 minutes. Unesterified heptadecanoic acid (17:0) was added as an internal standard to the plasma and total lipids were extracted with the Folch method. The total lipid extract was separated by thin layer chromatography on 60 A° silica gel plates (Whatman, Clifton, NJ) alongside phospholipid, unesterified fatty acids, triglyceride and cholesteryl ester standards using the solvent system heptane: diethylether:glacial acetic acid (60:40:3, v/v/v). The plates were sprayed with 0.03% 6-p-toluidine-2-naphthalene-sulfonic acid in 50 mM Tris--HCl buffer (pH7.4) (w/v), and the unesterified fatty acids band was identified under UV light, scraped and methylated with 1% H~2~SO~4~ (by vol) in anhydrous methanol (3 h at 70°C) after adding 0.2 ml toluene. The fatty acid methyl esters were extracted with 3 ml heptane after terminating the reaction with 1.5 ml water \[[@CR33]\], reconstituted in 25 μl of isooctane and quantified by gas chromatography as described \[[@CR30]\]. The injection volume was 2 μl.

Quantitative autoradiography {#Sec7}
----------------------------

Quantitative autoradiography was performed on a total of 81 brain regions from autoradiographs of coronal brain sections. The regions were identified from a stereotaxic rat brain atlas \[[@CR34]\], and were sampled in both hemispheres. The average of bilateral measurements for each region from three consecutive brain sections was used to calculate regional radioactivity (nCi/g wet brain) by digital quantitative densitometry, using the public domain 1.62 Analysis NIH Image program. Regional brain incorporation coefficient k\* (ml plasma/s/g wet brain) of \[1-^14^C\]DHA were calculated as follows \[[@CR35]\]:

where (nCi/g wet brain wt) is brain radioactivity 20 min after infusion, (nCi/ml plasma) is arterial unesterified \[1-^14^C\]DHA concentration, and *t* (min) is time after beginning \[1-^14^C\]DHA infusion. Integrated plasma radioactivity (integral of c\*~plasma~.dt), which corresponds to the input function, was determined by trapezoidal integration and used to calculate k\*.

The regional rate of incorporation of unesterified DHA from plasma into brain phospholipids, *J*~in~ (nmol/s/g), was calculated as follows \[[@CR30], [@CR36], [@CR37]\]:

where c~plasma~ is the plasma concentration (nmol/ml) of unlabeled unesterified DHA. Since negligible amounts of DHA (\<1%) can be synthesized *de novo* by the brain from its precursor, alpha-linolenic acid \[[@CR30], [@CR36]\], *J*~*in*~ represents the metabolic loss of DHA by the brain \[[@CR35]\].

Statistical analysis {#Sec8}
--------------------

All data are presented as mean ± SD. An unpaired t-test was used to assess significant changes in body weight, baseline body temperature, arterial blood pressure and heart rate, input function, the incorporation coefficient (k\*) and the incorporation rate, *J*~*in*~. A paired t-test was applied to compare mean body temperature, blood pressure and heart rate in the same animal before and after saline or quinpirole injection. Statistical significance was accepted at p \< 0.05.

Results {#Sec9}
=======

Physiological parameters {#Sec10}
------------------------

One control rat died after surgery and prior to infusion with saline due to unknown causes. During the brain slicing, one control and one quinpirole brains were not sectioned uniformly, resulting in a saturated, unquantifiable signal, and a sample size of 6 saline and 7 quinpirole. Physiological parameters, plasma input function and fatty acid concentrations were therefore obtained from 6 saline and 7 quinpirole treated rats.

Table [1](#Tab1){ref-type="table"} shows bodyweight, body temperature, arterial blood pressure, heart rate and orofacial activity, before and after saline or quinpirole treatment. Body weight did not differ significantly between the groups. Baseline body temperature was within physiological range (36.5-37.5°C) for both groups. Baseline body temperature, heart rate and systolic and diastolic blood pressure did not differ significantly (P \> 0.05 by unpaired t-test).Table 1**Physiological parameters before and after saline or quinpirole administration to unanesthetized rats**Saline (n = 6)Quinpirole (n = 7)BeforeAfterBeforeAfterBody weight (g)336 ± 22331 ± 13Rectal temperature (°C)36.5 ± 1.037.1 ± 0.237.2 ± 0.336.6 ± 0.1\*\*Heart rate (beats/min)434 ± 36393 ± 50441 ± 22444 ± 20Arterial blood pressure (mm Hg)Systolic182 ± 19164 ± 33182 ± 7178 ± 13Diastolic102 ± 1388 ± 25104 ± 695 ± 14Number of rats with orofacial activity^1^0/60/60/77/7^1^Orofacial activity, consisting of head tremors and sniffing was observed for 10 minutes after saline or quinpirole injection. All quinpirole-treated rats exhibited characteristic head tremors and sniffing activity within 2 minutes of drug injection. Values are mean ± SD of n = 6 saline and 7 quinpirole treated rats per group. \*\*P \< 0.01 compared to before quinpirole injection by paired t-test.

Heart rate and systolic and diastolic blood pressures did not significantly change after saline or quinpirole injection, compared to baseline (P \> 0.05 by paired t-test). Body temperature did not change also after saline injection, but was significantly reduced by 0.6°C after quinpirole injection (P \< 0.01 by paired t-test; Table [1](#Tab1){ref-type="table"}).

All quinpirole-treated rats but not controls exhibited orofacial head- and sniffing activity between 2 to 10 minutes after quinpirole injection, as reported \[[@CR16]\]. No convulsions were observed in either group.

Plasma input function {#Sec11}
---------------------

The plasma \[1-^14^C\]DHA-time curve is shown in Figure [1](#Fig1){ref-type="fig"}. Mean integral radioactivity over time, which represents the input function, did not differ significantly between saline and quinpirole treated rats (quinpirole, 183834 ± 51257 nCi/ml/s, n = 7 versus saline, 184872 ± 49596 nCi/ml/s, n = 6), consistent with our previous report \[[@CR38]\].Figure 1^**14**^ **C-DHA plasma radioactivity over 20 minutes in rats administered acute 1 mg/kg i.v. dose of (−)-quinpirole hydrochloride dissolved in 0.9% saline or vehicle consisting of 0.9% saline.** Solid line represents saline treated rats; dashed line represents quinpirole treated rats. Values are mean ± SD of n = 6 saline and 7 quinpirole treated rats per group.

Plasma unesterified fatty acid concentrations {#Sec12}
---------------------------------------------

Plasma unesterified fatty acid concentrations, including DHA concentration, did not differ significantly between the groups (Additional file [1](#MOESM1){ref-type="media"}: Table S1). DHA concentration was 13 ± 2 nmol/ml (n = 6) in controls, and 17 ± 4 nmol/ml (n = 7) in quinpirole treated rats (p = 0.096).

Incorporation coefficient (k\*) {#Sec13}
-------------------------------

Mean values of DHA incorporation coefficient k\* in acute saline- and quinpirole- treated rats are presented in Table [2](#Tab2){ref-type="table"}. Regional k\* values ranged between 3.4 to 15.9 ml/s/g × 10^−4^ in saline-treated control rats, consistent with our previous report \[[@CR16]\]. There was no significant difference in k\* between quinpirole-treated and control rats in any of the 81 brain regions examined. A representative autoradiogram comparing the DHA signal following saline or quinpirole is shown in Figure [2](#Fig2){ref-type="fig"}.Table 2**Mean values of \[1-** ^**14**^ **C\] docosahexaenoic acid incorporation coefficient k\*in acute saline- and quinpirole-treated rats**Brain regionSaline (n = 6)Quinpirole (n = 7)***Telencephalon***Prefrontal cortex layer I3.42 ± 0.873.00 ± 0.73Prefrontal cortex layer IV3.76 ± 0.983.66 ± 1.21Primary olfactory cortex3.28 ± 0.853.77 ± 1.76Frontal cortex (10)Layer I3.13 ± 0.793.88 ± 1.54Layer IV3.51 ± 1.004.26 ± 1.67Frontal cortex (8)Layer I3.38 ± 0.913.76 ± 1.77Layer IV3.66 ± 1.024.13 ± 1.91Pyriform cortex3.29 ± 0.603.12 ± 0.92Anterior cingulate cortex4.18 ± 0.935.06 ± 2.80Motor cortexLayer I3.35 ± 0.713.60 ± 1.39Layer II -- III3.72 ± 0.884.39 ± 1.74Layer IV4.00 ± 0.924.42 ± 1.59Layer V3.35 ± 0.793.64 ± 1.35Layer VI3.25 ± 0.613.50 ± 1.29Somatosensory cortexLayer I3.61 ± 0.834.01 ± 1.57Layer II--III3.97 ± 0.884.68 ± 1.92Layer IV4.20 ± 1.034.57 ± 1.73Layer V4.09 ± 0.904.51 ± 1.72Layer VI3.93 ± 0.894.44 ± 1.72Auditory cortexLayer I4.09 ± 1.364.51 ± 1.29Layer IV4.07 ± 1.234.11 ± 1.22Layer VI3.62 ± 1.213.82 ± 1.18Visual cortexLayer I3.44 ± 1.104.17 ± 1.37Layer IV3.92 ± 1.244.52 ± 1.35Layer VI3.77 ± 1.144.38 ± 1.30Preoptic area (LPO/MPO)3.39 ± 0.763.48 ± 1.12Suprachiasmatic nu3.55 ± 0.903.73 ± 1.18Globus pallidus3.28 ± 0.713.83 ± 1.38Bed nu striaterminalis3.44 ± 0.763.58 ± 1.15Olfactory tubercle4.41 ± 1.064.39 ± 1.34Diagonal bandDorsal4.36 ± 1.073.92 ± 1.31Ventral4.11 ± 1.053.80 ± 1.36Amygdala basolat/med3.95 ± 0.863.65 ± 0.96HippocampusCA13.91 ± 0.853.36 ± 0.77CA24.00 ± 0.913.41 ± 0.80CA34.11 ± 0.923.69 ± 0.86Dentate gyrus4.29 ± 0.994.18 ± 1.05SLM4.49 ± 1.014.91 ± 1.92Accumbens nucleus3.45 ± 0.833.33 ± 1.16Caudate putamenDorsal4.33 ± 1.003.67 ± 1.40Ventral4.35 ± 1.093.80 ± 1.29Lateral4.39 ± 1.003.76 ± 1.34Medial4.36 ± 1.043.68 ± 1.32Septal nucleus lateral3.90 ± 0.883.31 ± 1.20medial4.19 ± 1.013.84 ± 1.15***Diencephalon***Habenular nu lateral5.50 ± 1.155.75 ± 1.85Habenular nu medial5.48 ± 1.675.12 ± 1.60Lateral geniculate nu dorsal4.61 ± 1.914.19 ± 1.16Medial geniculate nu4.59 ± 1.814.83 ± 1.61ThalamusVentroposterior lateral nu4.78 ± 2.144.08 ± 0.96Ventroposterior medial nu4.99 ± 2.154.31 ± 1.06Paratenial nu4.61 ± 0.884.46 ± 1.76Anteroventral nu5.91 ± 1.265.84 ± 2.41Anteromedial nu4.95 ± 1.114.61 ± 1.77Reticular nu4.98 ± 1.094.93 ± 2.08Paraventricular nu4.41 ± 0.874.23 ± 1.68Parafascicular nu4.88 ± 1.314.85 ± 1.70Subthalamic nucleus4.77 ± 1.474.93 ± 1.71HypothalamusSupraoptic nu5.09 ± 1.475.34 ± 1.41Lateral3.89 ± 0.933.75 ± 1.29Anterior3.91 ± 1.003.90 ± 1.25Periventricular3.40 ± 1.003.29 ± 1.05Arcuate4.32 ± 1.204.66 ± 1.79Ventromedial4.03 ± 1.134.54 ± 1.87Posterior4.52 ± 0.924.01 ± 1.43Mammillary nucleus3.99 ± 1.624.59 ± 1.48Zone Incerta4.36 ± 1.404.18 ± 1.27***Mesencephalon***Interpeduncular nucleus5.09 ± 1.425.89 ± 2.18Substantianigra3.50 ± 0.994.45 ± 1.75Pretectal area4.07 ± 1.184.92 ± 1.92Superior colliculus4.17 ± 1.075.38 ± 2.28Deep layers4.05 ± 1.254.71 ± 1.12Inferior colliculus6.62 ± 2.067.01 ± 2.52***Rhombencephalon***Flocculus5.67 ± 1.686.16 ± 2.24Cerebellar gray matter5.58 ± 1.656.59 ± 2.31Molecular layer cerebellargray matter6.54 ± 1.457.23 ± 2.96***White matter***Corpus callosum2.74 ± 0.682.74 ± 1.08Internal Capsule3.19 ± 0.783.30 ± 1.02Cerebellar white matter4.56 ± 1.675.38 ± 1.83***Non-blood--brain barrier regions***Subfornical organ4.02 ± 0.934.72 ± 3.10Median eminence5.03 ± 1.875.44 ± 1.73Choroid plexus15.89 ± 6.0716.66 ± 6.90k\* = (ml/s/g) x 10^−4^. Values are mean ± S.D of n = 6 saline and 7 quinpirole. Each region of interest was measured in sextuplicate in each rat.Figure 2**Representative autoradiogram of coronal brain slices showing** ^**14**^ **C-DHA radioactivity following acute vehicle consisting of 0.9% saline or 1 mg/kg i.v. dose of (−)-quinpirole hydrochloride dissolved in 0.9% saline.**

Incorporation rate (J~in~) {#Sec14}
--------------------------

Regional rates of unesterified DHA incorporation into the brain, calculated from the product of k\* and unesterified plasma DHA concentration (2), did not differ significantly between the groups in the 81 regions examined (data not shown). Mean J~in~ values in vehicle and quinpirole treated rats were 58.8 ± 20.8 and 73.6 ± 22.5 nmol/s/g×10^−4^, respectively (P \>0.05 by unpaired t-test).

Discussion and conclusions {#Sec15}
==========================

D2-like receptor activation by acute quinpirole did not significantly change brain DHA incorporation coefficient (k\*) or rate (J~in~) in any of the 81 regions studied. The incorporation coefficient k\* reflects the metabolic loss of DHA by the brain following its release from membrane phospholipid and J~in~ reflects net loss \[[@CR35]\]. The lack of a quinpirole effect on each parameter suggests that D2-like receptor activation does not involve DHA release from membrane phospholipid.

DHA release is controlled by iPLA~2~ \[[@CR3]\], which is activated following displacement of bound calmodulin protein by calcium influx factor \[[@CR23]\]. Intracellular calcium increases concurrently because it is released with the calcium influx factor from the ER/SR in response to IP~3~ formation following PLC stimulation \[[@CR19]--[@CR21]\]. Unlike iPLA~2~, cPLA~2~ requires extracellular calcium for activation \[[@CR3]\], consistent with in vivo evidence of increased AA but not DHA incorporation into the brain following glutamatergic NMDA receptor activation, which allows extracellular calcium into the cell \[[@CR16]\]. D2-like receptor stimulation also allows extracellular calcium into the cell, similar to NMDA \[[@CR28]\]. Thus, the increase in AA \[[@CR12], [@CR38]\] but not DHA incorporation (Table [2](#Tab2){ref-type="table"}) following acute quinpirole confirms the independence of iPLA~2~ of extracellular calcium and likely reflects selective coupling of D2-like receptors to cPLA~2~ but not iPLA~2~. Several in vitro studies reported a reduction in intracellular calcium levels following dopaminergic activation \[[@CR27], [@CR28]\]. The lack of effect of quinpirole on k\* agrees with these observations.

This study does not rule out the possibility that intracellular calcium levels increased following D2-receptor stimulation with quinpirole, as reported in vitro \[[@CR25]--[@CR28]\]. Such elevations if present, however, were not significant enough to produce a measurable DHA signal with our method.

This study demonstrates that there is no DHA signal following activation of D2-like receptors, although there is a signal following activation of muscarinic and serotonergic receptors \[[@CR9], [@CR17]\]. It is likely, therefore, that iPLA~2~ is activated by the latter two but not D2 receptors. The difference in G-protein receptor coupling remains to be clarified, but it may be related to limited intracellular calcium release and dissociation of calmodulin from iPLA~2~ following dopaminergic receptor stimulation, compared to muscarinic stimulation \[[@CR39]--[@CR42]\].

In summary, this study showed that D2-like receptor activation does not involve DHA release as a second messenger. This observation, along with our previous finding that D2-like receptor activation stimulates AA release, suggest that D2 receptors are selectively coupled to AA but not DHA as a second messenger.
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